Barclays
CMPI

Barclays’s Checkmate Pharmaceuticals, Inc. Common Stock CMPI Stock Holding History

Barclays’s Portfolio CMPI Stock Details CMPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-14,553
Closed -$46K – 5493
2022
Q1 		$46K Buy
+14,553
New +$41.9K ﹤0.01% 4153

Barclays's CMPI Position: Q2 2022 in Review

Barclays sold out of Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) in Q2 2022, closing a stake of 14,553 shares — an estimated $46K sold.

Barclays first reported a position in CMPI in Q1 2022 and held it in 1 quarter. The position peaked at $46K in Q1 2022. 0 funds tracked by Wall St. Rank hold CMPI as of Q2 2022.

  • Barclays reported no remaining Checkmate Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Barclays sold 14,553 Checkmate Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $46K.
  • Barclays first reported a position in Checkmate Pharmaceuticals, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Barclays's Checkmate Pharmaceuticals, Inc. Common Stock position peaked at $46K in Q1 2022.
  • 0 funds tracked by Wall St. Rank held Checkmate Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.